Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma

[1]  R. Warnick,et al.  In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. , 1993, Human gene therapy.

[2]  R. Arceci,et al.  Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  I. Pastan,et al.  P-glycoprotein and multidrug resistance. , 1996, Current opinion in genetics & development.

[4]  M. Boyd,et al.  In vivo studies on the relationship between target organ alkylation and the pulmonary toxicity of a chemically reactive metabolite of 4-ipomeanol. , 1978, The Journal of pharmacology and experimental therapeutics.

[5]  K. Dobberstein,et al.  A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma. , 1998, Advances in experimental medicine and biology.

[6]  P. Galle,et al.  Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. , 1997, The Journal of clinical investigation.

[7]  B. O’Malley,et al.  Combination gene therapy for oral cancer in a murine model. , 1996, Cancer research.

[8]  J. Trinchet,et al.  Treatment of hepatocellular carcinoma in patients with cirrhosis. , 1997, Journal of hepatology.

[9]  H. Blum,et al.  Primary hepatocellular carcinoma. , 1991, The New England journal of medicine.

[10]  J. Prieto,et al.  Gene Therapy of Liver Tumors: Principles and Applications , 1998, Digestion.

[11]  J. Roh,et al.  Combined use of tamoxifen, cyclosporin A, and verapamil for modulating multidrug resistance in human hepatocellular carcinoma cell lines. , 1993, Yonsei medical journal.

[12]  S. Hirohashi,et al.  p53 gene mutation spectrum in hepatocellular carcinoma. , 1992, Cancer research.

[13]  D. Dinsdale,et al.  CYP4B1 activates 4-ipomeanol in rat lung. , 1993, Toxicology and applied pharmacology.

[14]  V. Mazzaferro,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[15]  D. Israeli,et al.  p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.

[16]  S. Kuriyama,et al.  Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma , 1995, Hepatology.

[17]  M. Christian,et al.  Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  X. Breakefield,et al.  Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. , 1998, Journal of the National Cancer Institute.

[19]  J. Wands,et al.  p53 mutation in hepatocellular carcinoma after aflatoxin exposure , 1991, The Lancet.

[20]  C. Contant,et al.  Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. , 1996, Cancer research.

[21]  M. Boyd,et al.  The in vitro formation of glutathione conjugates with the microsomally activated pulmonary bronchiolar aklylating agent and cytotoxin, 4-ipomeanol. , 1980, The Journal of pharmacology and experimental therapeutics.

[22]  J. Gebert,et al.  Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. , 1998, Human gene therapy.

[23]  J. Wands,et al.  The increasing incidence of hepatocellular carcinoma. , 1999, The New England journal of medicine.

[24]  C. Wolf,et al.  Cytochrome p-450: localization in rabbit lung. , 1980, Science.

[25]  Bert Vogelstein,et al.  p53 function and dysfunction , 1992, Cell.

[26]  C. Qian,et al.  Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus‐mediated gene transfer of herpes simplex virus thymidine kinase , 1995, Hepatology.

[27]  F. Ponchel,et al.  Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis. , 1994, Cancer research.

[28]  K. Dobberstein,et al.  New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. , 1998, Human gene therapy.

[29]  H. Wakimoto,et al.  In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. , 1997, Cancer research.

[30]  J. Wands,et al.  Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa , 1991, Nature.

[31]  E K Fishman,et al.  Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans. , 1993, Cancer research.

[32]  M. Boyd.  Role of metabolic activation in the pathogenesis of chemically induced pulmonary disease: mechanism of action of the lung-toxic furan, 4-ipomeanol. , 1976, Environmental health perspectives.

[33]  H. El‐Serag,et al.  Rising incidence of hepatocellular carcinoma in the United States. , 1999, The New England journal of medicine.

[34]  M. Boyd,et al.  Species and strain differences in target organ alkylation and toxicity by 4-ipomeanol. Predictive value of covalent binding in studies of target organ toxicities by reactive metabolites. , 1979, Biochemical pharmacology.

[35]  J. Bruix,et al.  Treatment of hepatocellular carcinoma. , 2006, Critical reviews in oncology/hematology.

[36]  K. Korzekwa,et al.  Metabolic activation of 4-ipomeanol by complementary DNA-expressed human cytochromes P-450: evidence for species-specific metabolism. , 1991, Cancer research.

[37]  J. Gu,et al.  Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. , 1992, Journal of the National Cancer Institute.

[38]  S. Freeman,et al.  The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. , 1993, Cancer research.